Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | PTH1R | Q03431 | 5/20 | 0.38 |
| ▸ | PRF1 | P14222 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL848079 | 0.85 | PTH1R (0.46) | PTH1R | |
| SCHEMBL16302311 | 0.85 | PARP1 (0.39) | PRF1PARP1NPY5RMEN1KMT2A | |
| SCHEMBL16302288 | 0.83 | PTH1R (0.40) | PTH1R | |
| SCHEMBL849398 | 0.82 | PTH1R (0.38) | PTH1R | |
| SCHEMBL10290600 | 0.81 | PARP1 (0.36) | CHRNA7PRF1PARP1NPY5RMEN1 | |
| SCHEMBL16358550 | 0.81 | PARP1 (0.36) | CHRNA7PRF1PARP1NPY5RMEN1 | |
| SCHEMBL849742 | 0.80 | KMT2A (0.46) | MEN1KMT2AHTTGAAMAPT | |
| SCHEMBL13551986 | 0.80 | MEN1 (0.33) | PTH1RNPY5RMEN1KMT2A | |
| SCHEMBL13552134 | 0.80 | PTH1R (0.39) | CHRNA7PTH1RMEN1KMT2A | |
| SCHEMBL849731 | 0.79 | HSD11B1 (0.49) | MEN1KMT2AHTTGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162208-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-05-26 | — | — | US | disclosed |
| US-20220162208-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-05-26 | — | — | US | disclosed |
| US-20210024524-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-01-28 | — | — | US | disclosed |
| US-20210024524-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-01-28 | — | — | US | disclosed |
| US-20180237436-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-08-23 | — | — | US | disclosed |
| US-9993462-B2 | Hydantoin derivative-containing pharmaceutical composition | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-12 | — | — | US | disclosed |
| US-9993462-B2 | Hydantoin derivative-containing pharmaceutical composition | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-12 | — | — | US | disclosed |
| US-9993462-B2 | Hydantoin derivative-containing pharmaceutical composition | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-12 | — | — | US | disclosed |
| EP-2930176-B1 | HYDANTOIN DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-2930176-B1 | HYDANTOIN DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-2930176-A1 | HYDANTOIN DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-10-14 | — | — | EP | disclosed |
| EP-2930176-A1 | HYDANTOIN DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-10-14 | — | — | EP | disclosed |
| US-20150274727-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-01 | — | — | US | disclosed |
| US-20150274727-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-01 | — | — | US | disclosed |
| US-20150274727-A1 | HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-01 | — | — | US | disclosed |
| WO-2014092061-A1 | HYDANTOIN DERIVATIVE | 中外製薬株式会社 (JP) | 2014-06-19 | — | — | WO | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | CHRNA7 2523/4885PTH1R 1869/4885PRF1 4552/4885 |
| US-20210024524-A1 | HYDANTOIN DERIVATIVE | HRH4, HRH3, H1-3 | CHRNA7 2638/4885PTH1R 2316/4885PRF1 2335/4885 |
| US-20150274727-A1 | HYDANTOIN DERIVATIVE | HRH4, HRH3, H1-3 | CHRNA7 2638/4885PTH1R 2316/4885PRF1 2335/4885 |
| US-20180237436-A1 | HYDANTOIN DERIVATIVE | HRH4, HRH3, H1-3 | CHRNA7 2638/4885PTH1R 2316/4885PRF1 2335/4885 |
| US-20220162208-A1 | HYDANTOIN DERIVATIVE | HRH4, HRH3, H1-3 | CHRNA7 2638/4885PTH1R 2316/4885PRF1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.